1-ethyl-1H-pyrrole-3-carboxylic acid | 1245534-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-ethyl-1H-pyrrole-3-carboxylic acid
• 英文别名: 1-ethylpyrrole-3-carboxylic acid
• CAS: 1245534-90-0
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: HTNSSMUWGMGBMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  282.9±13.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethyl-1H-pyrrole-3-carboxylic acid 在 正丁基锂 、 叠氮磷酸二苯酯 、 sodium 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 苯 为溶剂， 反应 1.0h， 生成 (R)-5-methoxymethyl-3-(1-ethyl-1H-pyrrol-3-yl)-2-oxazolidinone
  参考文献：
  名称：

  Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1H-Pyrrol-3-yl)-2-oxazolidinones

  摘要：

  Monoamine oxidases (MAOs) are involved in various psychiatric and neurodegenerative disorders; hence, MAO inhibitors are useful agents in the therapy of Parkinson's disease, Alzheimer's dementia, and depression syndrome. Herein we report a novel series of 3-(1H-pyrrol-3-yl)-2-oxazolidinones 3-7 as reversible, highly potent and selective anti-MAO-A agents. In particular, 4b, 5b, and 4c showed a Ki-MAO-A of 0.6, 0.8, and I nM, respectively, 4c being 200000-fold selective for MAO-A with respect to MAO-B.

  DOI：

  10.1021/jm201011x
• 作为产物：
  描述：

  吡咯-3-甲醛 在 potassium permanganate 、 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 、 丙酮 为溶剂， 反应 0.83h， 生成 1-ethyl-1H-pyrrole-3-carboxylic acid
  参考文献：
  名称：

  Novel Reversible Monoamine Oxidase A Inhibitors: Highly Potent and Selective 3-(1H-Pyrrol-3-yl)-2-oxazolidinones

  摘要：

  Monoamine oxidases (MAOs) are involved in various psychiatric and neurodegenerative disorders; hence, MAO inhibitors are useful agents in the therapy of Parkinson's disease, Alzheimer's dementia, and depression syndrome. Herein we report a novel series of 3-(1H-pyrrol-3-yl)-2-oxazolidinones 3-7 as reversible, highly potent and selective anti-MAO-A agents. In particular, 4b, 5b, and 4c showed a Ki-MAO-A of 0.6, 0.8, and I nM, respectively, 4c being 200000-fold selective for MAO-A with respect to MAO-B.

  DOI：

  10.1021/jm201011x

文献信息

• [EN] NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULATEURS DU MÉTABOLISME CELLULAIRE ET LEURS UTILISATIONS
  申请人：CRESCENTA BIOSCIENCES

  公开号：WO2021150645A1

  公开（公告）日：2021-07-29

  A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

  一类化合物，能够结合到脂肪酸结合蛋白（FABP4）并调节脂肪细胞代谢以促进增强葡萄糖利用，以及包含该类化合物的药物组合物，与药用辅料或载体相结合，并可选地进一步与治疗活性剂相结合，以及这些化合物在医学上的应用和用于制备治疗作用于FABP4的疾病的药物。
• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• Pyrroloazepine derivatives
  申请人：SUNTORY LIMITED

  公开号：US20030166926A1

  公开（公告）日：2003-09-04

  A method of effecting serotonin-2-receptor antagonism in a mammal in need thereof, which includes administering to the mammal an effective amount of the compound of the formula (I), or a pharmaceutically acceptable salt thereof: 1 wherein ring P, the dashed line, A, Y, Z 1 and Z 2 are defined herein.

  一种在需要的哺乳动物中实现5-羟色胺2受体拮抗的方法，其包括向哺乳动物施用公式(I)的化合物或其药学上可接受的盐的有效量：1其中环P，虚线，A，Y，Z1和Z2在此被定义。
• Compounds having lysophosphatidic acid receptor antagonism and uses thereof
  申请人：Tanaka Motoyuki

  公开号：US20070149595A1

  公开（公告）日：2007-06-28

  The present invention relates to a compound represented by formula (I): (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic hypertrophy or neurogenic bladder dysfunction disease, spinal cord neoplasm, nucleous hernia, spinal canal stenosis, diseases caused by diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, and polyuria), carcinoma-associated disease, proliferative disease, inflammation system disease, immune system disease, disease by secretory dysfunction, brain-related disease and/or chronic disease.

  本发明涉及一种由式(I)表示的化合物：（其中式中的符号在说明中被描述），其盐，溶剂化物或前药。由于本发明的化合物与LPA受体（特别是EDG-2）结合并具有拮抗作用，因此它对预防和/或治疗泌尿系统疾病（前列腺增生或神经源性膀胱功能障碍疾病，脊髓肿瘤，核突出，脊柱管狭窄，由糖尿病引起的疾病，下尿路梗阻疾病，下尿路炎症性疾病和多尿症），癌症相关疾病，增殖性疾病，炎症系统疾病，免疫系统疾病，分泌功能障碍疾病，与大脑相关的疾病和/或慢性疾病具有用处。